Fund+

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

AstriVax is a biotechnology company focused on developing innovative vaccines that address significant challenges in the field of vaccinology. The company aims to achieve initial clinical validation of its platform technology, which is designed to create a diverse pipeline of vaccines. AstriVax's vaccine candidates are engineered to minimize cold chain requirements, making them more accessible and easier to distribute. Additionally, these vaccines are intended to provide broad and long-lasting protection against a variety of viruses and pathogens, thereby enhancing treatment options within the healthcare sector.

eTheRNA Immunotherapies NV is a Belgium-based biotechnology company that specializes in the development of mRNA-based immunotherapies. Founded in 2013 and located in Niel, the company focuses on harnessing the immune system's dendritic cells to create treatments for melanoma, triple-negative breast cancer, and infectious diseases. eTheRNA has developed innovative TriMix technology that enhances the immune response, enabling patients to better combat these diseases. The company aims to be a leader in nucleic acid-based medicines, collaborating with partners to facilitate the creation of new drugs and improve patient outcomes. Additionally, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its mission.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

TargED Biopharmaceuticals is a biotechnology company focused on developing innovative biological drugs aimed at enhancing the treatment of thrombosis. The company utilizes small antibodies, known as VhH, to deliver enzymes directly to the sites of thrombus, facilitating targeted thrombolysis. This approach allows for effective treatment regardless of the blood clot's composition, thereby enabling healthcare professionals to accelerate patient care and improve outcomes for those affected by thrombosis.

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition historically managed with daily eye drops. EyeD Pharma aims to enhance the quality of life for patients by reducing the side effects associated with traditional therapies. In collaboration with ophthalmologists, the company offers new treatment options and surgical products that improve clinical practices and provide therapeutic assistance that is currently lacking in the market. Through its efforts, EyeD Pharma seeks to advance the standard of care in ophthalmology.

Egle Therapeutics SAS is a biotechnology company founded in 2020 and based in Paris, France. The company specializes in developing immunotherapies aimed at targeting immune suppressor regulatory T-cells (Tregs) to address oncology and autoimmune diseases. Egle Therapeutics is focused on its proprietary pipeline, which includes a series of computationally designed IL-2 variants designed to modulate Tregs by either engaging or disengaging them from tumor environments. Through its innovative approach to Treg modulation, the company aims to enable healthcare professionals to develop new therapies that effectively target these immune suppressor cells, potentially transforming treatment options for cancer and other diseases.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.

ExeVir Bio BV is a Belgian biotechnology company founded in 2020 and headquartered in Zwijnaarde. The company specializes in developing single-domain antibody-based therapies aimed at preventing viral infections. Utilizing a llama-derived antibody technology platform, ExeVir Bio focuses on creating robust antiviral treatments, particularly targeting coronaviruses. One of its key products, VHH72-FC, binds to a conserved region of the SARS-CoV-2 spike protein, which is crucial for the virus's entry into human cells. The company has established a rapid response platform for antivirals, allowing for a quick adaptation to emerging health threats through a streamlined process for generating drug candidates. Their protein-based therapeutics are designed to be stable, cost-effective, and accessible on a global scale, addressing significant public health challenges posed by viral infections.

eTheRNA Immunotherapies NV is a Belgium-based biotechnology company that specializes in the development of mRNA-based immunotherapies. Founded in 2013 and located in Niel, the company focuses on harnessing the immune system's dendritic cells to create treatments for melanoma, triple-negative breast cancer, and infectious diseases. eTheRNA has developed innovative TriMix technology that enhances the immune response, enabling patients to better combat these diseases. The company aims to be a leader in nucleic acid-based medicines, collaborating with partners to facilitate the creation of new drugs and improve patient outcomes. Additionally, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its mission.

Ona Therapeutics, S.L. is a biotechnology company founded in 2019 and based in Barcelona, Spain. It specializes in the discovery and development of therapeutic biologics that specifically target tumor metastatic-initiating cells and lipid metabolism. As a spin-off from ICREA and the IRB Institute for Research in Biomedicine, the company focuses on blocking the pathways involved in fat metabolism in animal models of cancer. Its innovative therapies aim to inhibit the cells responsible for metastasis, thereby preventing the development of malignant tumors and potentially eradicating existing ones. Ona Therapeutics is positioned to offer treatment solutions for various metastatic cancers, including those affecting the oral cavity, breast, ovaries, stomach, bladder, prostate, and melanoma.

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics aimed at improving outcomes for cancer patients. Founded in 2011 and headquartered in Gosselies, Belgium, with additional operations in Cambridge, Massachusetts, the company is advancing a pipeline of innovative drug candidates. Notable among these is EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing an open-label Phase 1/2a clinical trial in adult patients. Another key candidate is EOS-448, an antagonist of TIGIT, which is also in Phase 1/2a trials. iTeos leverages expertise in tumor immunology to create small molecule immunomodulators designed to counteract cancer-induced immune suppression, thereby enhancing the effectiveness of existing treatments and emerging immunotherapies.

EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition historically managed with daily eye drops. EyeD Pharma aims to enhance the quality of life for patients by reducing the side effects associated with traditional therapies. In collaboration with ophthalmologists, the company offers new treatment options and surgical products that improve clinical practices and provide therapeutic assistance that is currently lacking in the market. Through its efforts, EyeD Pharma seeks to advance the standard of care in ophthalmology.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics aimed at improving outcomes for cancer patients. Founded in 2011 and headquartered in Gosselies, Belgium, with additional operations in Cambridge, Massachusetts, the company is advancing a pipeline of innovative drug candidates. Notable among these is EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing an open-label Phase 1/2a clinical trial in adult patients. Another key candidate is EOS-448, an antagonist of TIGIT, which is also in Phase 1/2a trials. iTeos leverages expertise in tumor immunology to create small molecule immunomodulators designed to counteract cancer-induced immune suppression, thereby enhancing the effectiveness of existing treatments and emerging immunotherapies.

Aelin Therapeutics is a privately held Belgian biotherapeutics company founded in 2017, based in Heverlee. The company develops antibiotics and therapeutics using its proprietary Pept-in technology, which leverages protein aggregation to induce functional knockdown of target proteins. This approach allows for the rational design of novel biotherapeutics that can address undruggable human targets and combat resistant bacteria like Methicillin-resistant Staphylococcus aureus (MRSA). Aelin Therapeutics' platform offers a unique mode of action and intracellular target space, differentiating it from traditional small molecule drugs or protein-based therapeutics. The company's technology has shown applications in various areas including bacteria, cancer cells, fungi, viruses, and plant cells, with supporting preclinical Proof of Concept data published in high-impact journals such as Science.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

OCTIMET Oncology NV is a biotechnology company based in Beerse, Belgium, that specializes in developing MET kinase inhibitors for cancer treatment. Founded in 2016, the company focuses on advancing discovery-stage molecules, including cMET inhibitors and other selective anti-tumor agents. OCTIMET employs innovative strategies for patient selection and pharmacodynamic biomarkers to enhance the clinical development of its therapies. By utilizing biomarker-defined intelligent patient selection, OCTIMET aims to provide differentiated treatment options for patients with solid tumors, thereby improving outcomes within existing treatment paradigms.

Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics aimed at improving outcomes for cancer patients. Founded in 2011 and headquartered in Gosselies, Belgium, with additional operations in Cambridge, Massachusetts, the company is advancing a pipeline of innovative drug candidates. Notable among these is EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing an open-label Phase 1/2a clinical trial in adult patients. Another key candidate is EOS-448, an antagonist of TIGIT, which is also in Phase 1/2a trials. iTeos leverages expertise in tumor immunology to create small molecule immunomodulators designed to counteract cancer-induced immune suppression, thereby enhancing the effectiveness of existing treatments and emerging immunotherapies.